RenovoRx Files to Sell 6.96M Shares of Common Stock for Holders
RenovoRx Regains Nasdaq Compliance
RenovoRx Regains Nasdaq Compliance
RenovoRx Regains Compliance With Nasdaq Stockholders' Equity Requirement
Shaun Bagai, Chief Executive Officer of RenovoRx, stated, "Regaining compliance with Nasdaq's listing requirements represents another critical achievement for RenovoRx.
RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
Sub-study of the pivotal Phase III TIGeR-PaC clinical trial offers important data to potentially assist in optimization of TAMP therapy.
RenovoRx Secures $11.1M Through Equity and Warrants Offering
RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway Into 2026
RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced the closing of its previously announced private placement of approximately $11.1 million in gross proceeds.
RenovoRx Executes Definitive Subscription Agreement With Accredited Investors For $11.1M At Market Private Placement
Cash position now expected to fund current operating plan into 2026Financing provides cash runway to advance the ongoing pivotal Phase III TIGeR-PaC trial through the second interim readout and toward
RenovoRx Announces $11.1 Million at Market Private Placement
RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced the execution of definitive subscription agreements with accredited investors for a private placement which is expected to result in gross proceeds of approximately $11.1 million to RenovoRx, before deducting offering expenses.
Affimed N.V., Hutchmed, Annexon Among Healthcare Movers
RenovoRx Promotes Leesa Gentry to Chief Clinical Officer
RenovoRx Announces Key Leadership Promotions
RenovoRx Struggles to Avoid Nasdaq Delisting Amid Leadership Changes
RenovoRx Secures Funding for Phase III Cancer Trial
RenovoRx Initiated at Buy by Alliance Global Partners
RenovoRx Initiated at Buy by Alliance Global Partners
Alliance Global Partners Initiates Coverage On RenovoRx With Buy Rating, Announces Price Target of $4
Alliance Global Partners analyst Scott Henry initiates coverage on RenovoRx (NASDAQ:RNXT) with a Buy rating and announces Price Target of $4.
RenovoRx Closes $6.1M Private Placement
12 Health Care Stocks Moving In Wednesday's Intraday Session
GainersSana Biotechnology (NASDAQ:SANA) shares increased by 45.2% to $7.49 during Wednesday's regular session. The company's market cap stands at $1.4 billion. Amarin Corp (NASDAQ:AMRN) stock increase
Esperion Therapeutics, Voyager Therapeutics Among Healthcare Movers
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersLongboard Pharmaceuticals (NASDAQ:LBPH) shares moved upwards by 200.7% to $18.13 during Tuesday's regular session. The company's market cap stands at $432.5 million. NGM Biopharmaceuticals (NAS
Corcept Therapeutics, Adc Therapeutics Among Healthcare Movers
No Data